Figure 1 / 4



A
tumor area [mm²]
160
140
120
100
80
60
40
20
0
-20
4
8
12
16
20
24
28
32
36
40
time after tumor cell inoculation (days)
no treatment
vehicle
0,01mg/kg MF-T-SPDB-DM4
0,03mg/kg MF-T-SPDB-DM4
0,05mg/kg MF-T-SPDB-DM4
0,2mg/kg MF-T-SPDB-DM4
B
tumor area [mm²]
160
140
120
100
80
60
40
20
0
8
12
16
20
24
28
32
time after tumor cell inoculation (days)
no treatment
vehicle
0,2 mg/kg MF-T-SPDB-DM4

Figure 2 / 4



250
200
150
100
50
0
tumor area [mm²]
0
4
8
12
16
20
24
28
32
36
time after tumor cell inoculation [days]
vehicle
0.2 mg/kg antiLysozyme-SPDB-DM4
0.2 mg/kg MOR6640-SPDB-DM4
0.2 mg/kg MOR6640-SMCC-DM1
0.2 mg/kg MOR6640-(PEG)4-mal-DM1
0.2 mg/kg MOR6640-sulfo-SPDB-DM4

Figure 3 / 4




A
tumor area [mm²]
250
200
150
100
50
0
-50
4
8
12
16
20
24
28
32
36
40
44
time after tumor cell inoculation [days]
B
tumor area [mm²]
180
160
140
120
100
80
60
40
20
0
4
8
12
16
20
24
28
32
36
40
44
time after tumor cell inoculation [days]
vehicle
0.05 mg/kg antiLysozyme-SPDB-DM4
0.05 mg/kg MOR6640-SPDB-DM4
0.05 mg/kg MOR6640-SMCC-DM1
0.05 mg/kg MOR6640-(PEG)4-mal-DM1
0.05 mg/kg MOR6640-sulfo-SPDB-DM4

Figure 4 / 4


HELA-MATU
abs (405nm)
1.50
1.25
1.00
0.75
0.50
0.25
0.00
-3
-2
-1
0
1
2
3
log conc (nM)